Treanor C J, Li J, Donnelly M
Cancer Epidemiology and Health Services Research Group, Centre for Public Health, Queen's University, Belfast, UK.
Centre for Public Health, Queen's University, Belfast, UK.
Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12642. Epub 2017 Feb 7.
To identify and clarify definitions and methods of measuring cancer-related cognitive impairment among prostate cancer patients treated with androgen deprivation therapy (ADT) and to assess the incidence and prevalence of cognitive impairment. A systematic review of Medline, EMBASE, PubMed, PsycINFO and CINAHL up to December 2015 was undertaken to identify English-language reviews. A total of 28 reviews were identified describing 20 primary studies. There were no studies of incidence. Reported prevalence rates varied between 10% and 69%. Cognitive domains impaired by ADT included: verbal memory, visuospatial ability and executive functions. Cognitive impairment was infrequently defined and four definitions were reported. A variety of measures and methods were used to assess cognitive function including neuropsychological tests, self-report measures and clinical assessments. The finding that, often, one measure was used to assess more than one aspect of cognition is likely to have contributed to imprecise estimates. There is a need to agree a definition of cognitive impairment in the clinical epidemiology of cancer and to standardise the selection of measures in order to aid accurate assessment and fair comparisons across studies regarding the prevalence of cognitive impairment among prostate cancer patients.
确定并阐明接受雄激素剥夺疗法（ADT）的前列腺癌患者中癌症相关认知障碍的定义和测量方法，并评估认知障碍的发病率和患病率。对截至2015年12月的Medline、EMBASE、PubMed、PsycINFO和CINAHL进行系统综述，以识别英文综述。共识别出28篇综述，描述了20项主要研究。没有关于发病率的研究。报告的患病率在10%至69%之间。ADT导致受损的认知领域包括：言语记忆、视觉空间能力和执行功能。认知障碍的定义很少见，报告了四种定义。使用了多种测量方法来评估认知功能，包括神经心理学测试、自我报告测量和临床评估。通常使用一种测量方法来评估认知的多个方面这一发现可能导致了估计不准确。有必要在癌症临床流行病学中就认知障碍的定义达成一致，并规范测量方法的选择，以帮助准确评估并在各项研究之间就前列腺癌患者认知障碍的患病率进行公平比较。
